Europa Posted on 2026-06-12 10:16:00

UK approves weight loss pill - Novo Nordisk one more opportunity for European market

From SCAN TV

UK approves weight loss pill - Novo Nordisk one more opportunity for European

Britain's medicines regulator approved Novo Nordisk's weight-loss pill on Thursday, making the UK the first market in Europe where patients can access the pill-based treatment. The approval gives more than 10 million obese people in the UK an alternative to injections, as drugmakers race to expand the use of the drugs that have transformed weight-loss treatment and reshaped the global pharmaceutical industry.

The pill contains semaglutide, the same active ingredient as Novo's injectable drugs, Wegovy for weight loss and Ozempic for diabetes.

Novo received early approval in the United States for its weight-loss pill and launched there this year.

Analysts expect this market to exceed $100 billion in revenue by 2030. “For some people, a pill formula may make treatment more acceptable than injectable therapies,” said Dr. Marie Spreckley of the University of Cambridge, adding that the tablet should be taken on an empty stomach and 30 minutes before meals.

About 2.4 million people in the UK used GLP-1 drugs last year. Only about 200,000 of them received treatment through the state-run National Health Service, according to official figures. The rest got them privately, where the drugs can cost hundreds of pounds a month.

Britain's National Institute for Health and Care Excellence must assess the pill before it becomes available. Until then, patients can get the Wegovy pill through private providers, who will control its price, Novo said. A NICE spokesman said the agency was in active discussions with Novo, but that the company still had to submit a document of evidence for the institute to make a recommendation.

 

Live TV

Latest news
All news

Most visited